Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
80.42 CHF | -0.95% | -0.62% | +24.08% |
Mar. 07 | Switzerland's Bachem Reports Improved FY23 Net Income, Sales | MT |
Mar. 07 | Transcript : Bachem Holding AG, 2023 Earnings Call, Mar 07, 2024 |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company is in a robust financial situation considering its net cash and margin position.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 50.67 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Most analysts recommend that the stock should be sold or reduced.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+24.08% | 6.68B | B- | ||
+1.52% | 42.86B | B | ||
+13.09% | 42.74B | B- | ||
+44.87% | 41.36B | A | ||
-8.83% | 27.68B | C | ||
+7.12% | 25.15B | B- | ||
-23.13% | 18.63B | B | ||
+29.91% | 12.37B | C+ | ||
-2.77% | 11.92B | C+ | ||
+7.51% | 11.21B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BANB Stock
- Ratings Bachem Holding AG